CABP CE Bundle: 26 Credits (2024 Annual Meeting On-Demand Sessions)

For Recertifying CABPs Only – Exclusive AABB CABP CE Bundle

This specially priced bundle is designed to support current Certified Advanced Biotherapies Professionals (CABPs) in fulfilling their continuing education (CE) requirement. It includes 22 annual meeting on-demand sessions that collectively offer 26 CABP CE-eligible credits. All programs in this bundle are available online through AABB’s Education Platform as independent, self-paced learning programs. Upon purchase, you’ll receive immediate access via AABB’s Education Platform.

Important: Each session is available through December 31, 2026. CE credit must be claimed by this date.

2024 Annual Meeting On-Demand sessions included:

• AM24-ST-01-O: The Use of HLA-Typed Cellular Transfusions and/or Infusions for In Vivo Adsorption of Donor-Specific HLA Antibodies (DSAs) as a Desensitization Strategy for Hematopoietic Stem Cell Transplant Patients
• AM24-ST-09-O: Sterility Testing for Cellular Therapies: Updates and Challenges. What Should We Be Doing?
• AM24-ST-15-O: Sickle Cell Disease Psychosocial Support and Advocacy
• AM24-ST-20-O: Enhancing Laboratory Competency with AI: Meeting AABB Standards for Cell Processing Facilities and Blood Banks
• AM24-ST-21-O: Critical Role of an Assay Lifecycle in Analytical Development for Cell and Gene Therapy Products
• AM24-SN-01-O: The Future of Cellular Therapy Using Mesenchymal Stromal Cells and Dendritic Cells
• AM24-SN-06-O: Operationalizing Delivery of Gene Therapy for Sickle Cell Disease
• AM24-SN-09-O: Lesson's Learned Onboarding Cell and Gene Therapy Vendors and Clients in the 21st Century
• AM24-SN-17-O: Sickle Cell Disease: Inching Towards Transfusion Independence. Exploring the Journey from Chronic Transfusions to the Novel Biotherapeutics
• AM24-SN-19-O: Viral Vector Systems and Cellular Therapy
• AM24-MN-01-O: Source Plasma for Further Manufacture and Transfusion Medicine – Finding Common Ground
• AM24-MN-09-O: Management of Hematotoxicity from Immune Effector Cell Therapy and Sickle Cell Disease Gene Therapy
• AM24-MN-18-O: Mechanisms of Hematopoietic Stem Cells Towards Rejuvenation of the Aging Hematopoietic System
• AM24-MN-26-O: Overview of Cell-Based Biologics Manufacturing as a Contracted Service
• AM24-MN-31-O: Cell Therapy: Creative Inventory Management & Discard
• AM24-MN-32-O: Lyophilized, Stem-cell Derived, and Synthetic Platelet Products are Closer Than You May Think
• AM24-MN-34-O: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation
• AM24-TU-01-O: Beyond CAR T: Non-Conventional Applications of CAR Technology in Biotherapies
• AM24-TU-03-O: Addressing Racial Disparities Across Donation Products for Marginalized Peoples
• AM24-TU-06-O: Oral Abstracts - Biotherapy Spotlight
• AM24-TU-10-O: Is Your Firm Ready for an FDA Office of Inspections and Investigations Inspection? Hear about the Most Frequently Cited Observations and Inspectional Process from FDA’s Office of Biologics Inspectorate
• AM24-TU-11-O: Managing Risk, Maximizing Safety: The Essentials of Proactive Risk Assessment